82_FR_17916 82 FR 17846 - National Institute on Drug Abuse; Notice of Closed Meeting

82 FR 17846 - National Institute on Drug Abuse; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 70 (April 13, 2017)

Page Range17846-17847
FR Document2017-07508

Federal Register, Volume 82 Issue 70 (Thursday, April 13, 2017) 
[Federal Register Volume 82, Number 70 (Thursday, April 13, 2017)]
[Notices]
[Pages 17846-17847]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-07508]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel, SBIR PHASE II--Development & Manufacturing of 
Pharmaceutical Products for Addiction Treatment (1210, 1211, 1212, 
1213).
    Date: May 23, 2017.
    Time: 10:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852, (Telephone Conference 
Call).
    Contact Person: Lyle Furr, Scientific Review Officer, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.

(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)


[[Page 17847]]


    Dated: April 10, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-07508 Filed 4-12-17; 8:45 am]
 BILLING CODE 4140-01-P

17846 Federal Register / Vol. 82, No. 70 / Thursday, April 13, 2017 / Notices The meeting will be open to the www.drugabuse.gov/NACDA/ Contact Person: Jay R Radke, Ph.D., AIDS public as indicated below, with NACDAHome.html, where an agenda and Review Branch, Scientific Review Program, attendance limited to space available. any additional information for the meeting Division of Extramural Activities, Room will be posted when available. #3G11B, National Institutes of Health, NIAID, Individuals who plan to attend and need special assistance, such as sign (Catalogue of Federal Domestic Assistance 5601 Fishers Lane MSC–9823, Bethesda, MD Program Nos.: 93.279, Drug Abuse and 20892–9823, (240) 669–5046, jay.radke@ language interpretation or other Addiction Research Programs, National nih.gov. reasonable accommodations, should Institutes of Health, HHS) notify the Contact Person listed below (Catalogue of Federal Domestic Assistance in advance of the meeting. Dated: April 10, 2017. Program Nos. 93.855, Allergy, Immunology, The meeting will be closed to the Natasha M. Copeland, and Transplantation Research; 93.856, public in accordance with the Program Analyst, Office of Federal Advisory Microbiology and Infectious Diseases provisions set forth in sections Committee Policy. Research, National Institutes of Health, HHS) 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., [FR Doc. 2017–07507 Filed 4–12–17; 8:45 am] Dated: April 10, 2017. as amended. The grant applications BILLING CODE 4140–01–P Natasha M. Copeland, and/or contract proposals and the Program Analyst, Office of Federal Advisory discussions could disclose confidential Committee Policy. trade secrets or commercial property DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2017–07506 Filed 4–12–17; 8:45 am] such as patentable material, and personal information concerning BILLING CODE 4140–01–P individuals associated with the grant National Institutes of Health applications and/or contract proposals, National Institute of Allergy and DEPARTMENT OF HEALTH AND the disclosure of which would Infectious Diseases; Notice of Closed HUMAN SERVICES constitute a clearly unwarranted Meetings invasion of personal privacy. National Institutes of Health Name of Committee: National Advisory Pursuant to section 10(d) of the Council on Drug Abuse. Federal Advisory Committee Act, as National Institute on Drug Abuse; Date: May 2, 2017. amended (5 U.S.C. App.), notice is Notice of Closed Meeting Closed: 9:00 a.m. to 10:30 a.m. hereby given of the following meetings. Agenda: To review and evaluate grant The meetings will be closed to the Pursuant to section 10(d) of the applications and/or proposals. Place: National Institutes of Health, public in accordance with the Federal Advisory Committee Act, as Neuroscience Center, 6001 Executive provisions set forth in sections amended (5 U.S.C. App), notice is Boulevard, Rockville, MD 20852. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., hereby given of the following meeting. Open: 10:45 a.m. to 5:00 p.m. as amended. The grant applications and The meeting will be closed to the Agenda: This portion of the meeting will the discussions could disclose public in accordance with the be open to the public for announcements and reports of administrative, legislative, and confidential trade secrets or commercial provisions set forth in sections program developments in the drug abuse property such as patentable material, 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., field. and personal information concerning as amended. The contract proposals and Place: National Institutes of Health, individuals associated with the grant the discussions could disclose Neuroscience Center, 6001 Executive applications, the disclosure of which confidential trade secrets or commercial Boulevard, Rockville, MD 20852. would constitute a clearly unwarranted property such as patentable material, Contact Person: Susan R.B. Weiss, Ph.D., invasion of personal privacy. and personal information concerning Director, Division of Extramural Research, Name of Committee: National Institute of individuals associated with the contract Office of the Director, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Allergy and Infectious Diseases Special proposals, the disclosure of which Boulevard, NSC, Room 5274, MSC 9591, Emphasis Panel, Silencing of HIV–1 would constitute a clearly unwarranted Rockville, MD 20892, 301–443–6487, Proviruses (R61/R33). invasion of personal privacy. sweiss@nida.nih.gov. Date: May 8–9, 2017. Name of Committee: National Institute on Any member of the public interested in Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant Drug Abuse Special Emphasis Panel, SBIR presenting oral comments to the committee PHASE II—Development & Manufacturing of may notify the Contact Person listed on this applications. Place: National Institutes of Health, 5601 Pharmaceutical Products for Addiction notice at least 10 days in advance of the Fishers Lane, 4H200A/B, Rockville, MD Treatment (1210, 1211, 1212, 1213). meeting. Interested individuals and 20892, (Telephone Conference Call). Date: May 23, 2017. representatives of organizations may submit a letter of intent, a brief description of the Contact Person: Chelsea D. Boyd, Ph.D., Time: 10:00 a.m. to 12:00 p.m. organization represented, and a short Scientific Review Officer, Scientific Review Agenda: To review and evaluate contract description of the oral presentation. Only one Program, DEA/NIAID/NIH/DHHS, 5601 proposals. representative of an organization may be Fishers Lane, MSC–9823, Rockville, MD Place: National Institutes of Health, allowed to present oral comments and if 20852–9834, 240–669–2081, chelsea.boyd@ Neuroscience Center, 6001 Executive accepted by the committee, presentations nih.gov. Boulevard, Rockville, MD 20852, (Telephone may be limited to five minutes. Both printed Name of Committee: National Institute of Conference Call). and electronic copies are requested for the Allergy and Infectious Diseases Special Contact Person: Lyle Furr, Scientific record. In addition, any interested person Emphasis Panel, NIAID Clinical Trial asabaliauskas on DSK3SPTVN1PROD with NOTICES Review Officer, Office of Extramural Affairs, may file written comments with the Implementation Cooperative Agreement National Institute on Drug Abuse, NIH, committee by forwarding their statement to (U01). DHHS, Room 4227, MSC 9550, 6001 the Contact Person listed on this notice. The Date: May 8, 2017. Executive Boulevard, Bethesda, MD 20892– statement should include the name, address, Time: 11:00 a.m. to 5:00 p.m. 9550, (301) 827–5702, lf33c.nih.gov. telephone number and when applicable, the Agenda: To review and evaluate grant business or professional affiliation of the applications. (Catalogue of Federal Domestic Assistance interested person. Place: National Institutes of Health, 5601 Program No.: 93.279, Drug Abuse and Information is also available on the Fishers Lane, Rockville, MD 20892, Addiction Research Programs, National Institute’s/Center’s home page: (Telephone Conference Call). Institutes of Health, HHS) VerDate Sep<11>2014 17:51 Apr 12, 2017 Jkt 241001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\13APN1.SGM 13APN1

Federal Register / Vol. 82, No. 70 / Thursday, April 13, 2017 / Notices 17847 Dated: April 10, 2017. Room 7353, 6707 Democracy Boulevard, Days; CCRHB-Clinical Center Governing Natasha M. Copeland, Bethesda, MD 20892–2542, (301) 594–8898, Board Joint Session; Delayed Reporting Root barnardm@extra.niddk.nih.gov. Cause Analysis; Clinical Trials Support Program Analyst, Office of Federal Advisory This notice is being published less than 15 Realignment. Committee Policy. days prior to the meeting due to the timing Place: Conference Room 6C6 (except for [FR Doc. 2017–07508 Filed 4–12–17; 8:45 am] Clinical Center Tour), Building 31, National limitations imposed by the review and BILLING CODE 4140–01–P funding cycle. Institutes of Health, Bethesda, MD 20892. Closed: 3:20 p.m. to 5:00 p.m. (Catalogue of Federal Domestic Assistance Agenda: Identification of Candidates for Program Nos. 93.847, Diabetes, Leadership Roles. DEPARTMENT OF HEALTH AND Endocrinology and Metabolic Research; HUMAN SERVICES Place: Conference Room 6C6, Building 31, 93.848, Digestive Diseases and Nutrition National Institutes of Health, Bethesda, MD Research; 93.849, Kidney Diseases, Urology 20892. National Institutes of Health and Hematology Research, National Institutes Contact Person: Gretchen Wood, Staff of Health, HHS) Assistant, National Institutes of Health, National Institute of Diabetes and Dated: April 10, 2017. Office of the Director, One Center Drive, Digestive and Kidney Diseases; Notice Building 1, Room 126, Bethesda, MD 20892, of Closed Meetings David Clary, 301–496–4272, woodgs@od.nih.gov. Program Analyst, Office of Federal Advisory Pursuant to section 10(d) of the Committee Policy. Any interested person may file Federal Advisory Committee Act, as [FR Doc. 2017–07510 Filed 4–12–17; 8:45 am] written comments with the committee amended (5 U.S.C. App.), notice is BILLING CODE 4140–01–P by forwarding the statement to the hereby given of the following meetings. Contact Person listed on this notice. The The meetings will be closed to the statement should include the name, public in accordance with the DEPARTMENT OF HEALTH AND address, telephone number and when provisions set forth in sections HUMAN SERVICES applicable, the business or professional 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., affiliation of the interested person. as amended. The grant applications and National Institutes of Health In the interest of security, NIH has the discussions could disclose instituted stringent procedures for confidential trade secrets or commercial Office of the Director; Notice of entrance onto the NIH campus. All property such as patentable material, Meeting visitor vehicles, including taxicabs, and personal information concerning hotel, and airport shuttles will be Pursuant to section 10(d) of the inspected before being allowed on individuals associated with the grant Federal Advisory Committee Act, as applications, the disclosure of which campus. Visitors will be asked to show amended (5 U.S.C. App), notice is one form of identification (for example, would constitute a clearly unwarranted hereby given of a meeting of the NIH invasion of personal privacy. a government-issued photo ID, driver’s Clinical Center Research Hospital license, or passport) and to state the Name of Committee: National Institute of Board. purpose of their visit. Diabetes and Digestive and Kidney Diseases The meeting will be open to the Special Emphasis Panel; Loan Repayment public as indicated below, with Dated: April 7, 2017. Application Review. attendance limited to space available. Anna Snouffer, Date: April 27, 2017. Deputy Director, Office of Federal Advisory Individuals who plan to attend and Time: 2:00 p.m. to 5:00 p.m. Committee Policy. Agenda: To review and evaluate grant need special assistance, such as sign applications. language interpretation or other [FR Doc. 2017–07427 Filed 4–12–17; 8:45 am] Place: National Institutes of Health, Two reasonable accommodations, should BILLING CODE 4140–01–P Democracy Plaza, 6707 Democracy notify the Contact Person listed below Boulevard, Bethesda, MD 20892 (Telephone in advance of the meeting. Conference Call). The portion of the meeting devoted to DEPARTMENT OF HEALTH AND Contact Person: John F. Connaughton, the identification and evaluation of HUMAN SERVICES Ph.D., Chief, Scientific Review Branch, specific candidates for consideration for Review Branch, DEA, NIDDK, National leadership positions in the Clinical National Institutes of Health Institutes of Health, Room 7007, 6707 Democracy Boulevard, Bethesda, MD 20892– Center will be closed to the public in Office of the Director, Office of Science 5452, (301) 594–7797, connaughtonj@ accordance with the provisions set forth Policy; Meeting extra.niddk.nih.gov. in section 552b(c)(9)(B) and 552b(c)(6), This notice is being published less than 15 Title 5 U.S.C., as amended. Premature Pursuant to section 10(a) of the days prior to the meeting due to the timing disclosure of potential candidates and Federal Advisory Committee Act, as limitations imposed by the review and their qualifications, as well as the amended (5 U.S.C. App.), notice is funding cycle. discussions by the committee, could hereby given of the meeting of the Name of Committee: National Institute of significantly frustrate NIH’s ability to National Science Advisory Board for Diabetes and Digestive and Kidney Diseases recruit these individuals and the Biosecurity (NSABB). Special Emphasis Panel; Time-Sensitive consideration of personnel Name of Committee: National Science Obesity Policy and Program Evaluation. qualifications, performance, and the Advisory Board for Biosecurity. Date: April 28, 2017. competence of individuals as candidates Date: May 11, 2017. Time: 2:00 p.m. to 3:30 p.m. asabaliauskas on DSK3SPTVN1PROD with NOTICES would constitute a clearly unwarranted Time: 2:00 p.m.–4:30 p.m. Eastern. Agenda: To review and evaluate grant Agenda: Presentations and discussions applications. invasion of personal privacy. regarding: (1) The Blue Ribbon Panel draft Place: National Institutes of Health, Two Name of Committee: NIH Clinical Center report on the 2014 variola virus incident on Democracy Plaza, 6707 Democracy Research Hospital Board. the NIH Bethesda campus; (2) stakeholder Boulevard, Bethesda, MD 20892 (Telephone Date: April 28, 2017. engagement on implementation of the U.S. Conference Call). Open: 8:30 a.m. to 3:20 p.m. Government Policy for Institutional Contact Person: Michele L. Barnard, Ph.D., Agenda: Clinical Center Tour (8:30–9:45) Oversight of Life Sciences Dual Use Research Scientific Review Officer, Review Branch, Welcome and Board Chair’s Overview; NIH of Concern (DURC); and (3) other business of DEA, NIDDK, National Institutes of Health, Director’s Remarks, NIH CC CEO: First 100 the Board. VerDate Sep<11>2014 17:51 Apr 12, 2017 Jkt 241001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\13APN1.SGM 13APN1


Document Created: 2017-04-13 01:09:17
Document Modified: 2017-04-13 01:09:17
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesMay 23, 2017.
FR Citation82 FR 17846 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR